Neurological disorders represent major health concerns in terms of comorbidity and mortality worldwide. Despite a tremendous increase in our understanding of the pathophysiological processes involved in disease progression and prevention, the accumulated knowledge so far resulted in relatively moderate translational benefits in terms of therapeutic interventions and enhanced clinical outcomes. Aiming at specific neural molecular pathways, different strategies have been geared to target the development and progression of such disorders. The kallikrein-kinin system (KKS) is among the most delineated candidate systems due to its ubiquitous roles mediating several of the pathophysiological features of these neurological disorders as well as being implicated in regulating various brain functions. Several experimental KKS models revealed that the inhibition or stimulation of the two receptors of the KKS system (B1R and B2R) can exhibit neuroprotective and/or adverse pathological outcomes. This updated review provides background details of the KKS components and their functions in different neurological disorders including temporal lobe epilepsy, traumatic brain injury, stroke, spinal cord injury, Alzheimer's disease, multiple sclerosis and glioma. Finally, this work will highlight the putative roles of the KKS components as potential neurotherapeutic targets and provide future perspectives on the possibility of translating these findings into potential clinical biomarkers in neurological disease.
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The kallikrein-kinin system and its role in the brain
The kallikrein-kinin system (KKS) constitutes an inflammatory response system that influences the biological systems with a number of pleiotropic functions that have critical roles in vascular permeability and inflammation as well as thrombosis and blood coagulation (CostaNeto et al., 2008) . The discovery of the KKS and the subsequent studies that revealed its components dramatically increased our understanding of disease processes (Costa-Neto et al., 2008) . While the KKS plays a pivotal role in maintaining normal physiology such as vascular smooth muscle tone, its dysfunction yields detrimental outcomes to the organs involved (Marcondes and Antunes, 2005) . Indeed, the KKS has been linked to various disorders including: diabetic nephropathy and retinopathy (Jaffa et al., 2012; Liu and Feener, 2013) , cardiovascular diseases (Delemasure et al., 2013) and diseases of the kidney (Kakoki and Smithies, 2009 ). In addition, the KKS components identified in the nervous system influence the integrity of the neurovascular unit and participate in the progression of neurological diseases (Perry, 1991;  https://doi.org/10.1016/j.pneurobio.2018.01.003 Received 11 December 2017; Accepted 15 January 2018
